Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADAR-1 CRPC
2019-003761-17Phase 4Active
- Sponsor
- Policlinico Gemelli
- Start
- May 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of docetaxel, enzalutamide, abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Radiographic progression-free survival rate at 9 months. Started May 2021; status: active.
02
Drugs
docetaxelenzalutamideabirateroneprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2019-003761-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003761-17.